Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of LB P8 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT06699121 is registered in ClinicalTrials.gov with LISCure Biosciences as lead sponsor.

NCT NCT06699121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06699121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Study Evaluating the Safety and Efficacy of LB P8 in Patients With Primary Sclerosing Cholangitis (PSC)
Lead sponsor
LISCure Biosciences
Phase
Phase 2
Overall status
Recruiting
Start date
November 30, 2025
Completion date
February 28, 2029
Enrollment
87 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary sclerosing cholangitis (psc)